Eurofins Scientific (ERF) Q2 2024 earnings summary

Executive summary

• Achieved record H1 2024 revenues of €3,419m, up 6.5% year-over-year, driven by organic growth and acquisitions, surpassing pre-pandemic levels without COVID-19 related revenues.

• Adjusted EBITDA rose 18.3% to €757m (22.1% margin), with margin improving 220bps year-over-year; reported EBITDA margin improved 260bps to 20.9%.

• Net profit increased 46% to €220m; basic EPS rose 57% to €1.01; free cash flow before investment in owned sites surged 171% to €341m.

• Financial leverage reduced to 1.9x, within the 1.5–2.5x target range, with no major financing needs for 2024.

• Continued strong M&A activity, digitalisation, and infrastructure investments, including 15 acquisitions and 18 new start-up labs.

Financial highlights

• Revenue grew 6.5% year-on-year in H1, driven by 5.6% organic growth, 1.1% M&A contribution, and a -0.5% FX impact; reported revenues reached €3,419m.

• Adjusted EBITDA: €757m (22.1% margin), up from €640m (19.9%) in H1 2023; EBITDA cash conversion improved to 39%.

• Net profit surged 46% year-on-year to €220m; net profit margin rose to 6.4%.

• Free cash flow to the firm: €279m (+276% year-over-year); free cash flow before investment in owned sites: €341m (+171%).

• Net working capital intensity reduced to 6.3% of revenues, with DSO down one day and DPO up two days.

Outlook and guidance

• FY 2024 revenue objective: €7.075bn–€7.175bn; adjusted EBITDA: €1.525bn–€1.575bn; FCFF before investment in owned sites: €800–840m.

• Mid-term (2027) targets: revenues approaching €10bn, margin 24%, leverage below 1.5x, FCFF before investment in owned sites approaching €1.5bn.

• Organic growth target of 6.5% p.a. and €250m annual revenue from acquisitions through 2027.

• No change to annual objectives; expects continued margin and cash flow improvement as investments yield efficiencies.

• Biopharma segment remains soft but is expected to recover; overall outlook remains positive.